Abstract
Tenofovir disoproxil fumarate is a nucleotide analogue reverse transcriptase inhibitor approved by the FDA for the treatment of HIV infection. It is a potent agent with a long intracellular half-life that allows for once-daily dosing. It has been well tolerated in clinical trials, without evidence of the mitochondrial toxicity that has been associated with long-term treatment of some of the nucleoside analogue reverse transcriptase inhibitors. Because of its demonstrated efficacy and favourable safety profile, tenofovir disoproxil fumarate has quickly become a favoured nucleoside component of antiretroviral regimens for both treatment-naive and -experienced patients.
Original language | English (US) |
---|---|
Pages (from-to) | 459-469 |
Number of pages | 11 |
Journal | Expert Opinion on Drug Metabolism and Toxicology |
Volume | 2 |
Issue number | 3 |
DOIs | |
State | Published - 2006 |
Externally published | Yes |
Keywords
- AIDS
- Antiretroviral therapy
- HIV infection
- Nucleotide analogue reverse transcriptase inhibitor
- Tenofovir
ASJC Scopus subject areas
- Toxicology
- Pharmacology